Breast Cancer Core Needle Biopsy Market Overview:
As per MRFR analysis, the Breast Cancer Core Needle Biopsy Market Size was estimated at 3.51 (USD Billion) in 2022. The Breast Cancer Core Needle Biopsy Market Industry is expected to grow from 3.79 (USD Billion) in 2023 to 7.5 (USD Billion) by 2032. The Breast Cancer Core Needle Biopsy Market CAGR (growth rate) is expected to be around 7.87% during the forecast period (2024 - 2032).
Key Breast Cancer Core Needle Biopsy Market Trends Highlighted
The rising incidence of breast cancer, growing awareness of early detection techniques, and technological advancements in core needle biopsy drive the global breast cancer core needle biopsy market. Minimally invasive procedures, improved diagnostic accuracy, and increasing healthcare expenditure further contribute to market growth.
Trends in recent times include the adoption of vacuum-assisted breast biopsy (VABB) for improved sample collection, advancements in ultrasound-guided core needle biopsy (US-CNB) for real-time visualization, and the emergence of automated core needle biopsy devices for enhanced precision and accuracy.
Opportunities for market expansion exist in developing regions with limited access to advanced healthcare facilities, the integration of artificial intelligence (AI) for better image analysis, and the development of molecular biomarkers to guide treatment decisions.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Breast Cancer Core Needle Biopsy Market Drivers
Increasing Prevalence of Breast Cancer
Breast cancer is the most common cancer among women worldwide, with an estimated 2.3 million new cases and 685,000 deaths in 2020. The rising incidence of breast cancer is primarily attributed to factors such as increasing age, lifestyle changes, and environmental factors.
As the population ages, the risk of developing breast cancer increases. Additionally, lifestyle factors such as obesity, lack of physical activity, and unhealthy diets have been linked to an increased risk of breast cancer.
Environmental factors, such as exposure to certain chemicals and radiation, have also been implicated in the development of breast cancer. The increasing prevalence of breast cancer has led to a growing demand for diagnostic procedures, including core needle biopsies.
Core needle biopsies are minimally invasive procedures that allow physicians to obtain tissue samples from the breast for examination under a microscope. This helps in the accurate diagnosis of breast cancer and in determining the appropriate course of treatment.
The Global Breast Cancer Core Needle Biopsy Market Industry is expected to witness significant growth over the forecast period due to the rising incidence of breast cancer and the increasing adoption of core needle biopsies as a diagnostic tool.
Technological Advancements
Technological advancements have significantly improved the accuracy and efficiency of core needle biopsies. The development of new imaging techniques, such as ultrasound and MRI-guided biopsies, has allowed physicians to target specific areas of the breast with greater precision.
Additionally, the introduction of automated core needle biopsy systems has streamlined the procedure, reducing the time and discomfort associated with the biopsy. Technological advancements have also led to the development of new biopsy devices with smaller needles and improved sampling capabilities.
These devices minimize tissue damage and provide high-quality tissue samples for analysis. The availability of advanced biopsy devices has contributed to the growing adoption of core needle biopsies in the diagnosis of breast cancer.
Rising Awareness and Early Detection Initiatives
Increased awareness about breast cancer and the importance of early detection have contributed to the growth of the Global Breast Cancer Core Needle Biopsy Market Industry.
Government and healthcare organizations have implemented various initiatives to promote breast cancer awareness and encourage women to undergo regular screening. These initiatives have led to an increase in the number of women seeking diagnostic procedures, including core needle biopsies.
Early detection of breast cancer is crucial for successful treatment and improved patient outcomes. Core needle biopsies play a vital role in the early detection of breast cancer by providing accurate and timely diagnosis. The growing emphasis on early detection and the increasing awareness about breast cancer are expected to drive the demand for core needle biopsies in the coming years.
Breast Cancer Core Needle Biopsy Market Segment Insights:
Breast Cancer Core Needle Biopsy Market Target Tissue Insights
The Global Breast Cancer Core Needle Biopsy Market is segmented into various segments including Target Tissue. Target Tissue is categorizing the market into Breast, Prostate, Lung, Liver, Kidney and others. Among them, Breast segment held the largest share of the market in 2023.
The high prevalence of breast cancer and the increasing adoption of core needle biopsies for breast cancer diagnosis are major factors driving the growth of this segment. The increasing awareness of breast cancer and the importance of early detection are also contributing to the growth of the Breast segment.
The Prostate segment is also expected to witness significant growth over the forecast period. The increasing incidence of prostate cancer and the growing adoption of core needle biopsies for prostate cancer diagnosis are major factors driving the growth of this segment.
The Lung segment is expected to grow at a moderate rate during the forecast period due to the rising incidence of lung cancer and the increasing adoption of core needle biopsies for lung cancer diagnosis. The Liver segment is expected to grow at a steady pace over the forecast period.
The Kidney segment is expected to grow at a moderate rate due to the rising incidence of kidney cancer and the increasing adoption of core needle biopsies for kidney cancer diagnosis.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Breast Cancer Core Needle Biopsy Market Needle Size Insights
The Global Breast Cancer Core Needle Biopsy Market is segmented by needle size, with options including 14-Gauge, 16-Gauge, 18-Gauge, 20-Gauge, and 22-Gauge. Among these, the 14-Gauge needle segment holds a significant market share due to its ability to provide larger tissue samples, leading to more accurate diagnoses.
The 16-Gauge and 18-Gauge needle segments follow closely, offering a balance between sample size and patient comfort. The 20-Gauge and 22-Gauge needle segments are preferred for less invasive procedures and are gaining traction in outpatient settings.
The Global Breast Cancer Core Needle Biopsy Market revenue is expected to witness substantial growth in the coming years, driven by factors such as increasing breast cancer incidence, technological advancements, and rising healthcare expenditure.
Breast Cancer Core Needle Biopsy Market Modality Insights
The Global Breast Cancer Core Needle Biopsy Market segmentation by Modality includes Ultrasound-Guided, Stereotactic, and Other. Ultrasound-Guided segment held the largest market share of 42.1% in 2023 and is expected to continue its dominance throughout the forecast period.
The increasing adoption of ultrasound-guided core needle biopsy due to its accuracy, real-time visualization, and cost-effectiveness contributes to its market dominance. The stereotactic segment is projected to witness a significant growth rate of 8.2% during the forecast period, owing to the rising demand for minimally invasive procedures and technological advancements in stereotactic systems.
Other segments, which includes MRI-guided and vacuum-assisted core needle biopsy, is expected to grow steadily due to the expanding applications and improved accuracy of these techniques.
Breast Cancer Core Needle Biopsy Market Procedure Type Insights
The Global Breast Cancer Core Needle Biopsy Market is segmented by Procedure Type into Outpatient and Inpatient. Outpatient procedures account for a larger share of the market due to the increasing adoption of minimally invasive procedures and the convenience it offers to patients.
The rising number of outpatient surgery centers and the growing preference for same-day surgeries further contribute to the growth of this segment. Inpatient procedures, on the other hand, are preferred for complex cases that require specialized equipment or extended monitoring.
Despite the growing popularity of outpatient procedures, inpatient procedures are expected to maintain a steady share in the market due to the need for specialized care in certain cases. The Global Breast Cancer Core Needle Biopsy Market revenue from Outpatient procedures is projected to reach 2.65 billion USD by 2024.
Breast Cancer Core Needle Biopsy Market Biopsy Device Type Insights
The Global Breast Cancer Core Needle Biopsy Market is segmented by Biopsy Device Type into Vacuum-Assisted, Spring-Loaded, and Gravity-Fed. By 2024, the Vacuum-Assisted segment is projected to have a dominant market share, driven by the advantages it offers, including accurate tissue sampling, ease of use, and reduced patient discomfort.
Spring-Loaded devices are anticipated to hold a notable market share due to their precision and reliability in obtaining tissue samples. Gravity-Fed devices, while holding a smaller market share, are expected to witness steady growth due to their cost-effectiveness and simplicity of use.
The Global Breast Cancer Core Needle Biopsy Market is expected to grow significantly in the coming years, with increasing awareness about early detection and diagnosis of breast cancer, technological advancements, and supportive government initiatives.
Breast Cancer Core Needle Biopsy Market Regional Insights
The Global Breast Cancer Core Needle Biopsy Market is segmented into North America, Europe, Asia Pacific, South America, and Middle East Africa. North America is expected to hold the largest market share in 2023, owing to the high prevalence of breast cancer and the increasing adoption of core needle biopsy procedures. Europe is expected to be the second-largest market, followed by Asia Pacific.
The Asia Pacific region is expected to witness the fastest growth rate during the forecast period, due to the rising incidence of breast cancer and the increasing awareness of core needle biopsy procedures. South America and Middle East Africa are expected to contribute a smaller share to the global market.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Breast Cancer Core Needle Biopsy Market Key Players and Competitive Insights:
Major players in the Breast Cancer Core Needle Biopsy Market industry are continuously investing in research and development to enhance their product offerings and expand their market share. Leading Breast Cancer Core Needle Biopsy Market players are focused on developing innovative technologies and solutions to meet the evolving needs of healthcare professionals and patients.
The Breast Cancer Core Needle Biopsy Market development is driven by the increasing prevalence of breast cancer, advancements in medical imaging technologies, and the growing demand for minimally invasive procedures.
Hologic, Inc. is a leading player in the Breast Cancer Core Needle Biopsy Market industry. The company offers a comprehensive portfolio of breast biopsy systems and devices, including the Affirm Prone Breast Biopsy System, the Mammotome Revolve Biopsy System, and the ProCore Automated Breast Biopsy System.
Hologic, Inc. has a strong presence in both the US and international markets and is continuously investing in research and development to enhance its product offerings and expand its market share.
BD (Becton, Dickinson and Company) is another major player in the Breast Cancer Core Needle Biopsy Market industry. The company offers a wide range of biopsy systems and devices, including the Bard Magnum Core Biopsy Instrument, the Bard Max-Core Biopsy Instrument, and the Bard Precisio Core Biopsy Instrument.
BD (Becton, Dickinson and Company) has a global presence and is focused on developing innovative technologies and solutions to meet the evolving needs of healthcare professionals and patients.
Key Companies in the Breast Cancer Core Needle Biopsy Market Include:
- Invivo Medical
- BD
- AngioDynamics
- Hologic
- Cook Medical
- Carl Zeiss
- EndoClot Plus
- Argon Medical Devices
- R. Bard
- Medicsight Telemedicine Technology
- Cianna Medical
- Devicor Medical Products
- Olympus
- Leica Biosystems
- FUJIFILM Holdings
Breast Cancer Core Needle Biopsy Market Industry Developments
The increasing incidence of breast cancer, technological advancements in biopsy devices, and rising awareness about early detection are key factors driving market growth.
Recent developments include the launch of automated core needle biopsy systems and AI-powered image analysis software, enhancing accuracy and efficiency. Key players in the market include Becton, Dickinson and Company, Hologic, Inc., and Cook Medical.
Breast Cancer Core Needle Biopsy Market Segmentation Insights
- Breast Cancer Core Needle Biopsy Market Target Tissue Outlook
- Breast
- Prostate
- Lung
- Liver
- Kidney
- Breast Cancer Core Needle Biopsy Market Needle Size Outlook
- 14-Gauge
- 16-Gauge
- 18-Gauge
- 20-Gauge
- 22-Gauge
- Breast Cancer Core Needle Biopsy Market Modality Outlook
- Ultrasound-Guided
- Stereotactic
- Other
- Breast Cancer Core Needle Biopsy Market Procedure Type Outlook
- Outpatient
- Inpatient
- Breast Cancer Core Needle Biopsy Market Biopsy Device Type Outlook
- Vacuum-Assisted
- Spring-Loaded
- Gravity-Fed
- Breast Cancer Core Needle Biopsy Market Regional Outlook
- North America
- Europe
- South America
- Asia Pacific
- Middle East and Africa
| Report Attribute/Metric |
Details |
| Market Size 2022 |
3.51(USD Billion) |
| Market Size 2023 |
3.79(USD Billion) |
| Market Size 2032 |
7.5(USD Billion) |
| Compound Annual Growth Rate (CAGR) |
7.87% (2024 - 2032) |
| Report Coverage |
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Base Year |
2023 |
| Market Forecast Period |
2024 - 2032 |
| Historical Data |
2019 - 2023 |
| Market Forecast Units |
USD Billion |
| Key Companies Profiled |
Invivo Medical, BD, AngioDynamics, Hologic, Cook Medical, Carl Zeiss, EndoClot Plus, Argon Medical Devices, C.R. Bard, Medicsight Telemedicine Technology, Cianna Medical, Devicor Medical Products, Olympus, Leica Biosystems, FUJIFILM Holdings |
| Segments Covered |
Target Tissue, Needle Size, Modality, Procedure Type, Biopsy Device Type, Regional |
| Key Market Opportunities |
Rising prevalence of breast cancer Technological advancements in biopsy devices Increasing adoption of minimally invasive procedures Growing demand for early and accurate diagnosis Expansion of healthcare infrastructure in emerging markets |
| Key Market Dynamics |
Increasing breast cancer prevalence Technological advancements Growing adoption of minimally invasive procedures Government initiatives and reimbursement policies Rising demand for accurate and timely diagnosis |
| Countries Covered |
North America, Europe, APAC, South America, MEA |
Frequently Asked Questions (FAQ) :
The Global Breast Cancer Core Needle Biopsy Market was worth 3.79 billion USD in 2023.
The Global Breast Cancer Core Needle Biopsy Market is projected to grow at a CAGR of 7.87% from 2024 to 2032.
North America is expected to dominate the Global Breast Cancer Core Needle Biopsy Market throughout the forecast period.
Key applications of Breast Cancer Core Needle Biopsy include diagnostic evaluation of breast masses and lesions, staging of breast cancer, and monitoring response to treatment.
Key competitors in the Global Breast Cancer Core Needle Biopsy Market include Becton, Dickinson and Company, Hologic Inc., and C. R. Bard.
The Asia-Pacific region is expected to reach a market size of 1.2 billion USD by 2032.
Growth drivers of the Global Breast Cancer Core Needle Biopsy Market include increasing incidence of breast cancer, rising demand for minimally invasive procedures, and technological advancements.
Challenges faced by the Global Breast Cancer Core Needle Biopsy Market include high cost of procedures and reimbursement issues.
